<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104923</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000413887</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CCC-PHI-42</secondary_id>
    <secondary_id>NCI-6528</secondary_id>
    <secondary_id>LAC-USC-0C-04-3</secondary_id>
    <secondary_id>NCI-06-C-0227</secondary_id>
    <secondary_id>NCI-P6820</secondary_id>
    <nct_id>NCT00104923</nct_id>
  </id_info>
  <brief_title>Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer</brief_title>
  <official_title>Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>California Cancer Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
      Giving fenretinide in a different way may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of intravenous&#xD;
      fenretinide in treating patients with refractory or relapsed hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of intravenous emulsified fenretinide in patients&#xD;
           with refractory or relapsed hematologic malignancies.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and in vivo activity of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, disease or tumor response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a pilot, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive emulsified fenretinide IV continuously over 5 days. Treatment repeats every&#xD;
      21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients who achieve a complete or partial response may continue to receive fenretinide at&#xD;
      the discretion of the study chair.&#xD;
&#xD;
      Cohorts of 1 patient receive accelerated escalating doses of fenretinide until 2 patients&#xD;
      experience moderate toxicity (cumulative across all dose levels) OR 1 patient experiences&#xD;
      dose-limiting toxicity (DLT). After completion of the accelerated dose-escalation portion,&#xD;
      the standard dose-escalation portion begins. Cohorts of 3-6 patients receive escalating doses&#xD;
      of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as&#xD;
      the dose preceding that at which 2 of 6 patients experience DLT. At least 6 patients are&#xD;
      treated at the MTD. An additional 12 patients are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of fenretinide</measure>
    <time_frame>participants will be followed for the duration of cycle 1, which is expected to be 3 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe the toxicities of fenretinide</measure>
    <time_frame>participants will be followed for the duration of treatment, which is expected to be 18 weeks or less</time_frame>
  </primary_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenretinide</intervention_name>
    <description>Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following hematologic&#xD;
             malignancies:&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Chronic hematologic malignancy with a poor prognosis (e.g., failed 3 prior&#xD;
                  standard therapies), including any of the following:&#xD;
&#xD;
                    -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  Indolent NHL&#xD;
&#xD;
                    -  Myeloproliferative disorders&#xD;
&#xD;
          -  Refractory or relapsed disease, as defined by 1 of the following:&#xD;
&#xD;
               -  Resistant to standard therapy for refractory or relapsed disease&#xD;
&#xD;
               -  Progressed after standard therapy for advanced disease&#xD;
&#xD;
          -  No effective treatment exists&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No active CNS disease&#xD;
&#xD;
               -  Previously treated leptomeningeal disease or brain metastases allowed provided&#xD;
                  there is no evidence of remaining cancer by positron-emission tomography, MRI, or&#xD;
                  spinal fluid cytology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3 (unless due to bone marrow involvement of&#xD;
             disease)&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3 (unless due to bone marrow involvement of disease)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for patients with&#xD;
             liver metastasis)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No major cardiovascular disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No major respiratory disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception prior to study entry,&#xD;
             during study, and for at least 6 months after study participation&#xD;
&#xD;
          -  No uncontrolled systemic infection&#xD;
&#xD;
          -  No uncontrolled hypertriglyceridemia (i.e., triglyceride level &gt; 500 mg/dL)&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No known allergy to egg products&#xD;
&#xD;
          -  No known familial hyperlipidemia disorders&#xD;
&#xD;
          -  No previously undiscovered hypertriglyceridemia&#xD;
&#xD;
          -  No poorly controlled diabetes&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior chemotherapy except hydroxyurea&#xD;
&#xD;
               -  No concurrent hydroxyurea during study drug administration&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormone-ablative agents&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
          -  No concurrent tamoxifen or any of its analogues&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior cranial radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 20 days since prior surgery except for biopsy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 2 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No other concurrent antioxidants&#xD;
&#xD;
          -  No concurrent herbal or other alternative therapies&#xD;
&#xD;
          -  No concurrent vitamin supplements (e.g., vitamin A, ascorbic acid, or vitamin E)&#xD;
&#xD;
               -  Standard dose multivitamin allowed&#xD;
&#xD;
          -  No other concurrent medications that may act as modulators of intracellular ceramide&#xD;
             levels or ceramide cytotoxicity, sphingolipid transport, or p-glycoprotein or&#xD;
             multidrug resistance protein 1 (MRP1) drug/lipid transporters, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Cyclosporine or any of its analogues&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Chlorpromazine&#xD;
&#xD;
               -  Mifepristone&#xD;
&#xD;
               -  Indomethacin&#xD;
&#xD;
               -  Sulfinpyrazone&#xD;
&#xD;
          -  No concurrent medications that may cause pseudotumor cerebri, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Tetracycline&#xD;
&#xD;
               -  Nalidixic acid&#xD;
&#xD;
               -  Nitrofurantoin&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Sulfonamides&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
          -  No concurrent medication to control hypertriglyceridemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Mohrbacher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-9181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410-1894</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

